Last week, we shared our concern regarding a pending NGS decision to change the Medicare claim code for the administration of certolizumab peg from “Chemotherapy and Other Highly Complex Biologic Agent Administration” to “Therapeutic, Prophylactic, and Diagnostic Injections and Infusions.” Needless to say, the proposed change is very concerning and UR has written NGS and members of Congress explaining how the change threatens patient safety and undermines the ability of rheumatologists to provide care and services to our patient. Responding to our alert last week, a number of UR members sent letters to their elected officials highlighting the problems of this proposed change. Making elected officials and their staffs aware of changes like these is crucial to maintaining and improving the delivery of health care in our country.